The randomized clinical trial ADMIRAL randomized 371 patients with FLT3 mutated AML refractory to one or two cycles of conventional anthracycline-containing induction therapy or with hematologic relapse after complete remission. The gene discussed is FLT3; the disease is acute myeloid leukemia.